Defeat Duchenne Canada and Parent Project Muscular Dystrophy Award $300,000 (USD) Clinical Fellowship in Duchenne Endocrinology and Bone Fragility
Retrieved on:
Friday, November 3, 2023
Fertility, Steroid, Children's Hospital of Eastern Ontario, CHEO, Research, APRN, Louisiana Family Forum, Canada Research Chair, Bone, Endocrinology, Organization, Chronic kidney disease-mineral and bone disorder, University of Ottawa Heart Institute, Adrenal insufficiency, Vamorolone, Prednisone, PPMD, Male, Growth, Gender identity, Muscle weakness, University of Ottawa, Risk, Consortium, Duchenne muscular dystrophy, Partnership, DRS, University, Osteoporosis, Weakness, USD, Puberty, Education, DMD, Fracture, Muscular dystrophy, Hospital, Calvarial doughnut lesions-bone fragility syndrome, Human, Nursing, Dietary supplement, Medical device, Pediatrics, Duchenne
WASHINGTON and OTTAWA, ON, Nov. 3, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Defeat Duchenne Canada, Canada's leading charity fighting to defeat Duchenne, today announced a collaborative research award of $300,000 (USD) in support of two Clinical Fellowships in Duchenne Endocrinology and Bone Fragility. The three-year award will sponsor the extended fellowship of Dr. Kim Phung, as well as new fellow Dr. Rana Halloun, under the guidance of Dr. Leanne Ward, Professor of Pediatrics and Research Chair in Pediatric Bone Disorders at the University of Ottawa.
Key Points:
- Duchenne is the most common muscular dystrophy in children, affecting approximately one in 5,000 live male births.
- Duchenne is caused by a change in the dystrophin gene that leads to progressive muscle weakness.
- In 2021, Dr. Phung was awarded a two-year fellowship in pediatric endocrine and bone diseases at the University of Ottawa, with specific focus on endocrine and bone complications of Duchenne.
- Ward and Phung will delve into the latest developments and crucial topics related to bone health, growth, puberty, and adrenal insufficiency for Duchenne muscular dystrophy.